Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.93% on Wednesday, reaching $82.42. 6,711,405 shares of the company were exchanged. The stock has a 50-day moving average price of $80.40 and a 200 day moving average price of $71.48. The stock has a market capitalization of $107.63 billion, a price-to-earnings ratio of 8.95 and a beta of 1.14. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company’s revenue was down 8.2% on a year-over-year basis. During the same period last year, the firm posted $3.08 EPS. Analysts forecast that Gilead Sciences, Inc. will post $8.78 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Investors of record on Friday, September 15th were paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Insider John C. Martin Sells 73,333 Shares” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/04/gilead-sciences-inc-gild-insider-john-c-martin-sells-73333-shares.html.

A number of equities analysts have recently commented on GILD shares. William Blair reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 target price on the stock. in a research report on Wednesday, June 21st. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Leerink Swann reaffirmed a “market perform” rating on shares of Gilead Sciences in a research report on Thursday, June 22nd. Finally, Deutsche Bank AG started coverage on shares of Gilead Sciences in a research report on Friday, June 23rd. They set a “buy” rating and a $79.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $85.36.

A number of large investors have recently modified their holdings of GILD. Parnassus Investments CA boosted its stake in Gilead Sciences by 37.4% during the 1st quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after purchasing an additional 4,556,901 shares during the period. Bank of New York Mellon Corp boosted its stake in Gilead Sciences by 9.8% during the 1st quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after purchasing an additional 2,727,063 shares during the period. Renaissance Technologies LLC boosted its stake in Gilead Sciences by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock worth $736,667,000 after purchasing an additional 2,700,600 shares during the period. Vanguard Group Inc. boosted its stake in Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Gilead Sciences by 50.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock worth $438,244,000 after purchasing an additional 2,062,886 shares during the period. Hedge funds and other institutional investors own 73.99% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.